This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Genetic medicines developer Homology Medicines Inc. netted $135.1mm in its follow-on public offering of 6.39mm common shares (including full exercise of the overallotment) at $22.50. The company will use the proceeds to move its lead gene therapy program HMI102 for adults with phenylketonuria through a Phase I/II trial; to advance both HMI202 for metachromatic leukodystrophy and HMI103 for pediatric PKU through IND-enabling studies and possibly into the clinic; to move other pipeline programs through preclinical development; to further expand its intellectual property portfolio; and to potentially expand its manufacturing capacity.
Gene Therapy, Cell Therapy
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?